CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2020; 80(11): 1105-1114
DOI: 10.1055/a-1270-7208
GebFra Science
Review/Übersicht

Update Breast Cancer 2020 Part 3 – Early Breast Cancer

Article in several languages: English | deutsch
Jens Huober
1  Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Andreas Schneeweiss
2  National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
,
Andreas D. Hartkopf
3  Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
,
Volkmar Müller
4  Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Michael P. Lux
5  Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Germany
,
Wolfgang Janni
1  Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Johannes Ettl
6  Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
,
Erik Belleville
7  ClinSol GmbH & Co KG, Würzburg, Germany
,
Marc Thill
8  Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt, Germany
,
Peter A. Fasching
9  Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Hans-Christian Kolberg
10  Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
,
Carla E. Schulmeyer
9  Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Manfred Welslau
11  Onkologie Aschaffenburg, Aschaffenburg, Germany
,
Friedrich Overkamp
12  OncoConsult Overkamp, Berlin, Germany
,
Hans Tesch
13  Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany
,
Tanja N. Fehm
14  Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
,
Diana Lüftner
15  Charité University Hospital, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany
,
Florian Schütz
16  Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany
,
Achim Wöckel
17  Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
› Author Affiliations

Abstract

The treatment of patients with early breast cancer has always been characterised by escalation by new therapies and de-escalation through identification of better treatment regimens or introduction of better tools to estimate prognosis. Efforts in some of these areas in the last few years have led to solid data. The results of the large studies of de-escalation through use of multi-gene tests are available, as are the results of some studies that investigated the new anti-HER2 substances T-DM1 and pertuzumab in the early treatment situation. Several large-scale studies examining the role of CDK4/6 inhibitors will soon be concluded so innovations can be anticipated in this area also. This review article will summarise and classify the results of the latest publications.



Publication History

Received: 30 July 2020

Accepted after revision: 23 September 2020

Publication Date:
06 November 2020 (online)

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany